Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 5, 2026, 9:52 AM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1273–1296 of 14,134 matching trials from the live ClinicalTrials.gov search.

Filters: Intervention: Safety Control Clear all

Conditions: Cachexia; Cancer, Non Small Cell Lung Cancer
Interventions: Anamorelin Hydrochloride, Placebo Oral Tablet; Drug
Lead sponsor: Helsinn Healthcare SA; Industry
Eligibility: 18 Years and older
Enrollment: 318 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2023
U.S. locations: 24
States / cities: Tucson, Arizona • Little Rock, Arkansas • Riverside, California + 21 more

Conditions: Dementia Moderate, Dementia, Mild, Alzheimer Disease
Interventions: Xanamem, Placebo; Drug
Lead sponsor: Actinogen Medical; Industry
Eligibility: 50 Years and older
Enrollment: 247 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2028
U.S. locations: 19
States / cities: Carlsbad, California • Sherman Oaks, California • Denver, Colorado + 16 more

Conditions: Amplified Musculoskeletal Pain Syndrome (AMPS)
Interventions: Nerivio(R) Device, Usual Care; Device · Other
Lead sponsor: Children's Health; Other
Eligibility: 8 Years to 18 Years
Enrollment: 40 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2028
U.S. locations: 1
States / cities: Dallas, Texas

Conditions: Acute Intermittent Porphyria
Interventions: recombinant human porphobilinogen deaminase (Porphozym); Drug
Lead sponsor: Zymenex A/S; Industry
Eligibility: 18 Years and older
Enrollment: 36 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2003 – 2006
U.S. locations: 1
States / cities: Galveston, Texas

Conditions: Type 1 Diabetes Mellitus
Interventions: Heart rate informed SSM+HMM; Device
Lead sponsor: University of Virginia; Other
Eligibility: 21 Years to 65 Years
Enrollment: 12 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2012
U.S. locations: 1
States / cities: Charlottesville, Virginia

Conditions: Schizophrenia
Interventions: Paliperidone palmitate 25 mg eq., Paliperidone palmitate 150 mg eq., Placebo, Paliperidone palmitate 100 mg eq.; Drug
Lead sponsor: Johnson & Johnson Pharmaceutical Research & Development, L.L.C.; Industry
Eligibility: 18 Years and older
Enrollment: 652 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2007 – 2008
U.S. locations: 32
States / cities: Anaheim, California • Cerritos, California • Escondido, California + 29 more

Conditions: Rosacea, Papulopustular Rosacea
Interventions: 1% Topical Minocycline Gel, 3% Topical Minocycline Gel, Topical Vehicle Gel; Drug · Other
Lead sponsor: Hovione Scientia Limited; Industry
Eligibility: 18 Years and older
Enrollment: 270 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2019
U.S. locations: 23
States / cities: Bryant, Arkansas • Rogers, Arkansas • Fremont, California + 17 more

Conditions: Uveitis, Posterior, Uveitis, Intermediate
Interventions: V404; Drug
Lead sponsor: Forsight Vision4; Industry
Eligibility: 18 Years and older
Enrollment: 7 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2014 – 2015
U.S. locations: 5
States / cities: Golden, Colorado • Atlanta, Georgia • Omaha, Nebraska + 2 more

Conditions: Androgenetic Alopecia
Interventions: Topical SM04554 solution, Topical vehicle solution; Drug
Lead sponsor: Biosplice Therapeutics, Inc.; Industry
Eligibility: 18 Years to 55 Years · Male only
Enrollment: 302 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2014 – 2015
U.S. locations: 24
States / cities: Encinitas, California • San Diego, California • New Haven, Connecticut + 20 more

Conditions: Dementia of the Alzheimer's Type
Interventions: memantine ER, Placebo; Drug
Lead sponsor: Forest Laboratories; Industry
Eligibility: 50 Years and older
Enrollment: 677 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2005 – 2008
U.S. locations: 38
States / cities: Phoenix, Arizona • Costa Mesa, California • Fresno, California + 34 more

Conditions: ALS, Amyotrophic Lateral Sclerosis
Interventions: Fosigotifator, Placebo; Drug
Lead sponsor: AbbVie; Industry
Eligibility: 18 Years to 80 Years
Enrollment: 31 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2025
U.S. locations: 7
States / cities: Irvine, California • Los Angeles, California • San Francisco, California + 4 more

Conditions: Opioid-Induced Constipation
Interventions: Methylnaltrexone, Placebo; Drug
Lead sponsor: Bausch Health Americas, Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 237 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2008 – 2013
U.S. locations: 29
States / cities: Mobile, Alabama • Laguna Hills, California • Lancaster, California + 23 more

Conditions: Chronic Obstructive Pulmonary Disease (COPD)
Interventions: Indacaterol 150 μg, Tiotropium 18 μg, Placebo to indacaterol; Drug
Lead sponsor: Novartis Pharmaceuticals; Industry
Eligibility: 40 Years and older
Enrollment: 1,142 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2009 – 2010
U.S. locations: 116
States / cities: Anniston, Alabama • Birmingham, Alabama • Jasper, Alabama + 102 more

Conditions: Diabetic Gastroparesis
Interventions: 10 mg TZP-102, Placebo; Drug
Lead sponsor: Tranzyme, Inc.; Industry
Eligibility: 18 Years to 80 Years
Enrollment: 120 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2012 – 2013
U.S. locations: 23
States / cities: Huntsville, Alabama • Tucson, Arizona • North Little Rock, Arkansas + 19 more

Conditions: Pancreatic Cancer
Interventions: ABBV-927, Budiglimab, modified FOLFIRINOX; Drug
Lead sponsor: AbbVie; Industry
Eligibility: 18 Years to 75 Years
Enrollment: 40 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2024
U.S. locations: 5
States / cities: Aurora, Colorado • Baltimore, Maryland • Cleveland, Ohio + 1 more

Conditions: Pain
Interventions: HKT-500 Ketoprofen Topical Patch, Placebo Patch; Drug · Other
Lead sponsor: Hisamitsu Pharmaceutical Co., Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 368 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2008
U.S. locations: 35
States / cities: Birmingham, Alabama • Tempe, Arizona • Fullerton, California + 30 more

Conditions: Osteoarthritis of the Knee
Interventions: NKTR-181, Placebo; Drug
Lead sponsor: Nektar Therapeutics; Industry
Eligibility: 18 Years and older
Enrollment: 296 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2012 – 2013
U.S. locations: 34
States / cities: Mobile, Alabama • Tucson, Arizona • Garden Grove, California + 29 more

Conditions: Chronic Heart Failure
Interventions: conivaptan, placebo; Drug
Lead sponsor: Cumberland Pharmaceuticals; Industry
Eligibility: 18 Years and older
Enrollment: 170 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2002 – 2004
U.S. locations: 26
States / cities: Huntsville, Alabama • Los Angeles, California • Manteca, California + 22 more

Conditions: Autism Spectrum Disorder (ASD)
Interventions: BUMETANIDE (S95008) for week 0 - 26, PLACEBO for week 0 - 26, Open-Label BUMETANIDE (S95008) for weeks 26 - 52; Drug
Lead sponsor: Institut de Recherches Internationales Servier; Other
Eligibility: 2 Years to 6 Years
Enrollment: 211 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2021
U.S. locations: 1
States / cities: Staten Island, New York

Conditions: BK Virus Infection
Interventions: MAU868, Placebo; Drug · Other
Lead sponsor: Vera Therapeutics, Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 30 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2022
U.S. locations: 15
States / cities: Birmingham, Alabama • Los Angeles, California • New Haven, Connecticut + 11 more

Conditions: Obesity
Interventions: ERX1000, Placebo; Drug
Lead sponsor: ERX Pharmaceuticals; Industry
Eligibility: 18 Years to 55 Years
Enrollment: 48 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2023
U.S. locations: 1
States / cities: Madison, Wisconsin

Conditions: Crohn's Disease
Interventions: Ciprofloxacin, Placebo; Drug
Lead sponsor: University of North Carolina, Chapel Hill; Other
Eligibility: 18 Years to 70 Years
Enrollment: 33 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2008 – 2011
U.S. locations: 1
States / cities: Chapel Hill, North Carolina

Conditions: Dravet Syndrome
Interventions: LP352, Placebo; Drug
Lead sponsor: Longboard Pharmaceuticals; Industry
Eligibility: 2 Years to 65 Years
Enrollment: 108 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2026
U.S. locations: 25
States / cities: Little Rock, Arkansas • Los Angeles, California • Palo Alto, California + 20 more

Conditions: Enterotoxigenic E. Coli (ETEC) Infection
Interventions: ACE527 vaccine, Placebo vaccine; Biological
Lead sponsor: TD Vaccines A/S; Industry
Eligibility: 18 Years to 50 Years
Enrollment: 36 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2009
U.S. locations: 1
States / cities: Baltimore, Maryland

Search by objective public record fields.

A Study to Evaluate the Efficacy and Safety of Anamorelin HCl for the Treatment of Malignancy Associated Weight Loss and Anorexia in Adult Patients With Advanced Non-Small Cell Lung Cancer (NSCLC) - 1

Effect of 10 mg Xanamem on Dementia Due to Alzheimer's Disease

Efficacy and Safety of Nerivio for the Management of Amplified Musculoskeletal Pain Syndrome in Pediatric Patients

Porphozym in the Treatment of Acute Attacks in AIP

Feasibility Study of Closed Loop Control in Type 1 Diabetes Using Heart Rate Monitoring as an Exercise Marker

Effectiveness and Safety of 3 Fixed Doses (25 mg eq., 100 mg eq., and 150 mg eq.) of Paliperidone Palmitate in Patients With Schizophrenia

Study to Evaluate the Safety and Efficacy of Topical Minocycline Gel in Patients With Papulopustular Rosacea

Safety and Preliminary Efficacy Study of V404 PDS in Uveitis

A Study of the Safety, Tolerability, and Efficacy of Topical SM04554 Solution in Male Subjects With Androgenetic Alopecia (AGA)

A Study of the Safety and Efficacy of Memantine in Moderate to Severe Alzheimer's Disease

A Phase 1 Study to Investigate the Safety and Pharmacokinetics of Fosigotifator in Patients With Amyotrophic Lateral Sclerosis

Study Evaluating Subcutaneous Methylnaltrexone For Treatment Of Opioid-Induced Constipation In Patients With Advanced Illness

Efficacy and Safety of Indacaterol Plus Tiotropium Versus Tiotropium Alone in Patients With Chronic Obstructive Pulmonary Disease

Diabetic Gastroparesis Efficacy/Safety Study of TZP-102

Study to Evaluate Adverse Events and Change in Disease Activity When Intravenous (IV) Infusion of ABBV-927 is Administered in Combination With IV Modified FOLFIRINOX (mFFX) With or Without IV Budigalimab Compared to mFFX in Adult Participants With Untreated Pancreatic Cancer Metastasis

HKT-500 in Adult Patients With Shoulder Pain

A Phase 2 Study To Assess The Efficacy, Tolerability, And Safety OF NKTR-181 In Subjects With Chronic OA Knee Pain

Safety and Efficacy Study of YM087 (Conivaptan) in Patients With Acute Decompensated Heart Failure

Efficacy and Safety of Bumetanide Oral Liquid Formulation in Children Aged From 2 to Less Than 7 Years Old With Autism Spectrum Disorder.

A Safety, Pharmacokinetics and Efficacy Study of MAU868 for the Treatment of BK Viremia in Kidney Transplant Recipients

ERX1000 - Safety, Tolerability, Pharmacokinetic, and Pharmacodynamic Study in Male and Female Subjects With Obesity

Ciprofloxacin for the Prevention of Postoperative Endoscopic Recurrence in Crohn's Disease

A Phase 3, Placebo-Controlled Study to Investigate LP352 in Children and Adults With Dravet Syndrome (DS)

ACE527 Safety and Immunogenicity Study